<DOC>
	<DOCNO>NCT00082784</DOCNO>
	<brief_summary>Bortezomib may stop growth cancer cell block enzymes necessary growth . Drugs use chemotherapy , flavopiridol , work different way stop cancer cell divide stop grow die . Bortezomib may increase effectiveness flavopiridol make cancer cell sensitive drug . Giving bortezomib together flavopiridol may kill cancer cell . This phase I trial study side effect best dose bortezomib flavopiridol treat patient recurrent refractory indolent B-cell neoplasm .</brief_summary>
	<brief_title>Bortezomib Flavopiridol Treating Patients With Recurrent Refractory Indolent B-Cell Neoplasms</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To determine recommended phase II dose bortezomib flavopiridol patient recurrent refractory indolent B-cell neoplasm . SECONDARY OBJECTIVES : I . To determine toxic effect maximum tolerate dose regimen patient . II . To determine disease-related effect regimen patient . III . To determine pharmacodynamics regimen patient myeloma . IV . To determine pharmacokinetics regimen patient . OUTLINE : This dose-escalation , multicenter study . Patients receive bortezomib IV 3-5 second follow flavopiridol IV 1 hour day 1 , 4 , 8 , 11 . Courses repeat every 21 day absence disease progression unacceptable toxicity .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Lymphoma , Follicular</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Lymphoma , Mantle-Cell</mesh_term>
	<mesh_term>Lymphoma , B-Cell , Marginal Zone</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Waldenstrom Macroglobulinemia</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Alvocidib</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<criteria>WBC &lt; 50,000/mm^3 patient circulate tumor cell No prior allergic reaction compound similar chemical biological composition presumably able tolerate bortezomib , flavopiridol , allopurinol , sodium polystyrene sulfonate , dexamethasone No neuropathy &gt; = grade 2 No condition would preclude study participation Not pregnant nursing Fertile patient must use effective contraception 3 month study participation Prior autologous stem cell transplantation allow No prior allogeneic stem cell transplantation No concurrent anticancer agents No concurrent investigational agent Hemoglobin &gt; = 8 g/dL Platelet count &gt; = 100,000/mm^3 Absolute neutrophil count &gt; = 1,500/mm^3 Bilirubin = &lt; 2 time upper limit normal ( ULN ) AST/ALT = &lt; 3 time ULN Creatinine = &lt; 2 time ULN Creatinine clearance &gt; = 50 mL/min</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2014</verification_date>
</DOC>